Most Common Side Effects of Teriparatide
The most common side effects of teriparatide are mild and transient, including nausea, orthostatic hypotension (particularly with the first few doses), leg cramps, dizziness, and pain at the injection site. 1, 2
Primary Side Effects Profile
According to the 2020 AACE/ACE guidelines, the side effect profile of teriparatide is generally well-tolerated 1:
Most Frequent Adverse Effects:
- Nausea - One of the most commonly reported symptoms
- Orthostatic hypotension - Typically occurs with the first few doses, usually does not require discontinuation, and responds to lying down 1
- Leg cramps - Frequently reported in clinical trials 2
- Dizziness - Often associated with early doses 2
- Joint pain (arthralgia) - Common musculoskeletal complaint 3
Important Clinical Characteristics:
These side effects are characteristically mild and transient - they typically resolve without requiring drug discontinuation 1. The FDA drug label confirms that pain, nausea, and joint aches are the most common side effects 3.
Metabolic Effects
Hypercalcemia can occur but is uncommon, usually mild, asymptomatic, and transient 1. The FDA label notes that only 3% of women and 1% of men treated with teriparatide had verified transient hypercalcemia on consecutive measurements 3. When checking calcium levels, blood should be drawn at least 16 hours after drug administration 1.
Additional metabolic effects include:
- Increased serum uric acid (hyperuricemia in 3% vs 1% placebo), though this did not result in increased gout, arthralgia, or urolithiasis 3
- Increased urinary calcium excretion, though hypercalciuria frequency was similar to placebo 3
Early-Dose Precautions
For the first few doses, patients should inject teriparatide in a place where they can sit or lie down immediately in case of dizziness or abnormal heartbeat 3. This orthostatic effect typically occurs within 4 hours of injection and resolves within a few hours 3. Real-world data from Japan confirms dizziness as one of the most common adverse drug reactions (along with hyperuricemia and nausea) 4.
Serious Adverse Events
While the boxed warning about osteosarcoma exists (based on rat studies with very high doses), the actual human risk appears consistent with background incidence. Since teriparatide's introduction in 2002 with over 1 million users, the rate of osteosarcoma has not exceeded expected levels, with only one case reported as of 2016 2. Serious adverse drug reactions overall are rare, occurring in only 0.32% of patients in Japanese postmarketing surveillance 4.
Clinical Management Pearls
- Most adverse effects do not necessitate discontinuation 1
- The side effect profile is more favorable than initially feared based on extensive real-world experience 5, 4
- Injection site reactions (pain, swelling, bruising) can occur but are generally manageable 3
- Rare allergic reactions including anaphylaxis, angioedema, and urticaria have been reported in postmarketing surveillance 3
The key message for patients: while side effects like nausea, dizziness, and leg cramps are common, they are typically mild, temporary, and manageable, with most patients able to continue treatment successfully.